High blood pressure increases your risk of getting heart disease, kidney disease or serious stroke. Only Sunlighten infrared saunas are backed by clinical research that shows a reduction in systolic and diastolic blood pressure.
In a 2005 clinical study by the University of Missouri Kansas City, Sunlighten’s Solocarbon heaters were shown to lower blood pressure through a program of 30 minute infrared sauna session 3 times per week. In this double-blind placebo study, subjects were randomly assigned to receive sauna sessions in either the Sunlighten far infrared sauna or a look-a-like control sauna with a non-infrared heat source. The study concluded that the subjects using Sunlighten infrared sauna therapy showed a statistically significant reduction in both systolic and diastolic blood pressure – see study.
Additional studies have regularly shown the positive impact that regular infrared sauna use has on heart health. A study published in the Journal of the American College of Cardiology in 2001 showed that infrared saunas help improve the function of impaired vascular endothelial cells in patients who are at risk for coronary artery disease. The infrared heat of the sauna opens capillaries to improve blood flow. 15 minutes in an infrared sauna each day for 14 days improved the function of the endothelial cells lining the arteries by 40%.¹ The results of this study suggest a preventive role for infrared sauna use for arteriosclerosis.
The elevation in body temperature from regular Sunlighten infrared sauna use also produces an increase in blood flow that mirrors the benefits of a passive cardiovascular workout. Regular infrared sauna use has been shown to significantly stimulate blood flow, even after your sauna session is completed. Sunlighten’s mPulse 3-in-1 sauna has a built-in cardiovascular program using the optimal blend of infrared wavelengths for heart health.
For more information on infrared sauna use and heart health, connect with us directly at 877-292-0020.
¹Imamura, M, et al. Repeated thermal therapy improves impaired vascular endothelial function in patients with coronary risk factors. Journal of the American College of Cardiology. 2001, 38 (4): 1983-88.